| Literature DB >> 24984010 |
Sabrina Valetti1, Federica Maione2, Simona Mura3, Barbara Stella4, Didier Desmaële3, Magali Noiray3, Juliette Vergnaud3, Christine Vauthier3, Luigi Cattel4, Enrico Giraudo5, Patrick Couvreur6.
Abstract
Chemotherapy for pancreatic cancer is hampered by the tumor's physio-pathological complexity. Here we show a targeted nanomedicine using a new ligand, the CKAAKN peptide, which had been identified by phage display, as an efficient homing device within the pancreatic pathological microenvironment. Taking advantage of the squalenoylation platform, the CKAAKN peptide was conjugated to squalene (SQCKAAKN) and then co-nanoprecipitated with the squalenoyl prodrug of gemcitabine (SQdFdC) giving near monodisperse nanoparticles (NPs) for safe intravenous injection. By interacting with a novel target pathway, the Wnt-2, the CKAAKN functionalization enabled nanoparticles: (i) to specifically interact with both tumor cells and angiogenic vessels and (ii) to simultaneously promote pericyte coverage, thus leading to the normalization of the vasculature likely improving the tumor accessibility for therapy. All together, this approach represents a unique targeted nanoparticle design with remarkable selectivity towards pancreatic cancer and multiple mechanisms of action.Entities:
Keywords: Gemcitabine; Pancreatic cancer; Squalene nanoparticles; Targeted nanoparticles; Tumor-targeting peptide
Mesh:
Substances:
Year: 2014 PMID: 24984010 DOI: 10.1016/j.jconrel.2014.06.039
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776